$NBRV Longitude Capital Partners II, LLC filled a 13G as the beneficial owner of 4,256,527 shares of NBRV (up from 4, 012,375) representing a 4.5% ownership position. "Longitude Capital specializes in biotechnology and medical technology companies. "Our venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment. Following an initial investment, we work closely with our portfolio companies and syndicate partners to develop and implement strategic plans, achieve key operating objectives, build world class teams, raise capital and pursue liquidity opportunities in a manner that optimizes returns to key stakeholders."
  • 2
  • 3